Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Traditional and personalised models of therapy in gastrointestinal and endocrine tumours: the role of histological and clinical markers

17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress (ECC 2013)

Sorry, this item is currently unavailable.

Published: 8 Nov 2013

Views: 3561

Rating:

Save

Dr Jaume Capdevila - Vall d'Hebron University Hospita, Barcelona, Spain

Speaking at the AstraZeneca sponsored satellite symposium 'The revolution in peronalised healthcare: Towards improved outcomes in oncology', at the 2013 European Cancer Congress, Dr Capdevila discusses the role of histological and clinical markers in the modern field of personalised care for GI and endocrine tumours.

Related Videos

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer

Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy

Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer ( Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy )

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC

Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?

Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru

Targeting BRAF V600E in metastatic colorectal cancer: where are we today? ( Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru )

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC

Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC ( Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

Latest in PARP inhibitors and combination therapies for prostate cancer

Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou

Latest in PARP inhibitors and combination therapies for prostate cancer ( Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou )

Loco-regional management after neoadjuvant chemotherapy

Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA

Loco-regional management after neoadjuvant chemotherapy ( Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA )

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC

Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC ( Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

More from ecancer